C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDACTM Degrader of EGFR L858R for NSCLC

By
Jamie Kang
-
0
246
C4 Therapeutics, Inc. announced an exclusive licensing agreement for the development and commercialization of CFT8919 in Greater China (including Hong Kong SAR, Macau SAR, and Taiwan).
[C4 Therapeutics, Inc.]
Press Release